QS2: Aberrant Breast Adipose Stromal Cell Biology In Women At High Risk For Developing Breast Cancer
Taskindoust M., Xie T., Nelson V., Stukes B., Hollenbeck S., Bachelder R.
Prospective Study with a reported sample of 16, published in Plast Reconstr Surg Glob Open (2021) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Plast Reconstr Surg Glob Open (2021)
- Reported sample size
- 16
- Source database
- Europe PMC
- PMCID
- PMC8312789
Abstract (original English)
Purpose: Our laboratory studies contributions of breast adipose stromal cells (bASCs) to breast cancer initiation and progression. To date, most studies of ASC biology have focused on abdominal ASCs. We hypothesize that bASC biology impacts the breast microenvironment in a manner that influences a woman’s risk of developing breast cancer. Methods: In order to better understand how aberrant bASC biology contributes to breast cancer, we built a bASC cell repository from women undergoing mastectomies at Duke University Hospital (Duke IRB Pro00100739). Some of these women are at high risk for developing breast cancer. High risk biology includes women with genetic predispositions to cancer, as well as obese and post-menopausal women. bASCs were isolated from the stromal vascular fraction of breast adipose tissue from patients. Additionally, commercially-available ASCs isolated from the abdomen were obtained from Zenbio. Senescence was measured in bASCs using the SPiDER beta gal senescence detection kit (Dojingo). Senescence-associated cytokines were measured in conditioned media collected from these bASCs by ELISA (R&D Systems). The ability of bASCs to differentiate into adipocytes was measured using the Adipo-Red adipocyte differentiation assay (Lonza). Results: To date, we have isolated bASCs from 16 patients undergoing mastectomies at Duke University Hospital. We have studied dif
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.